JNJ.DE is trading 3.7% up at $218.60, fueled by the commercial launch of its Dual Energy THERMOCOOL SMARTTOUCH SF Platform in Europe today. The rally is further sustained by ongoing optimism surrounding its pharma pipeline, including recent positive clinical data for multiple myeloma and autoimmune hemolytic anemia treatments. Market sentiment remains strong, supported by a Buy consensus from analysts and a robust long-term growth narrative.